Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,619 result(s) found for: Renal. Displaying page 15 of 331.
    «« First « Previous 11  12  13  14  15  16  17  18  19  Next» Last»»
    EudraCT Number: 2011-002833-20 Sponsor Protocol Number: EP-TSC-663 Start Date*: 2012-08-20
    Sponsor Name:Oxford University Hospitals NHS Trust
    Full Title: Prospective study of 18F-RGD PET-CT in assessment of response to antiangiogenic treatment in patients with renal cancer and comparison with perfusion CT
    Medical condition: Primary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000380-26 Sponsor Protocol Number: CERTES02 (Ce-PoP-RAD001A2419) Start Date*: 2005-05-24
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3...
    Medical condition: Renal Transplant
    Disease: Version SOC Term Classification Code Term Level
    M15 10023438
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003114-34 Sponsor Protocol Number: CUR001 Start Date*: 2007-11-29
    Sponsor Name:Department of Nephrology and Renal Transplantation, University Hospitals Leuven
    Full Title: The impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients: exploratory investigation of the role of intestinal uridine-di...
    Medical condition: Stable renal allograft recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015987-32 Sponsor Protocol Number: AV-951-09-902 Start Date*: 2010-04-02
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000088-40 Sponsor Protocol Number: 07 300 02 Start Date*: 2008-04-09
    Sponsor Name:CHU de TOULOUSE
    Full Title: Pharmacocinétique de l’association pipéracilline-tazobactam chez les patients septiques, en insuffisance rénale oligo-anurique, traités par hémodiafiltration veino-veineuse continue
    Medical condition: patient septique hospitalisé en réanimation présentant une infection, déjà colonisé ou non, de localisation variable, à germe non identifié supposé sensible à l’association pipéracilline-tazobactam.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022519 Intensive care LLT
    9.1 10040580 Shock septic LLT
    9.1 10038435 Renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000127-32 Sponsor Protocol Number: ROPETAR Start Date*: 2011-11-03
    Sponsor Name:Werkgroep Immunotherapie Nederland voor Oncologie
    Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second lin...
    Medical condition: Advanced or metastatic clear cell renal cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038416 Renal clear cell carcinoma LLT
    16.1 100000004864 10009251 Clear cell carcinoma of the kidney LLT
    16.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000517-36 Sponsor Protocol Number: CRAD001H2401 Start Date*: 2005-09-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-b...
    Medical condition: maintenance of liver transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) ES (Completed) IT (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004606-97 Sponsor Protocol Number: PMR-EC-1209 Start Date*: 2007-02-22
    Sponsor Name:Astellas Pharma GmbH
    Full Title: A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY ...
    Medical condition: Stable, adult kidney transplant recipients (at least 12 months post transplant) who are currently treated with cyclosporine and who meet the Inclusion and Exclusion Criteria will be enrolled.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) HU (Completed) FI (Completed) SE (Completed) DK (Completed) AT (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003793-26 Sponsor Protocol Number: 3066K1-3311-WW Start Date*: 2008-05-19
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma
    Medical condition: First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) BE (Completed) PT (Completed) CZ (Completed) DE (Completed) SK (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004073-76 Sponsor Protocol Number: CAAA001A12401 Start Date*: 2020-10-12
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A multicenter, open-label post authorization safety study to evaluate the effect of LysaKare® infusion on serum potassium levels in GEP-NET patients eligible for Lutathera® treatment
    Medical condition: LysaKare® is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177 Lu) oxodotreotide in adults.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038428 Renal disorder PT
    20.1 10022117 - Injury, poisoning and procedural complications 10029140 Nephritis radiation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000796-32 Sponsor Protocol Number: 185/13 Start Date*: 2014-01-28
    Sponsor Name:Policlinico A. Gemelli
    Full Title: A multiple centre, randomised, open label, prospective clinical study to compare the efficacy and safety of a combination of tacrolimus with everolimus versus the combination of tacrolimus with MM...
    Medical condition: KIDNEY TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004947-23 Sponsor Protocol Number: none Start Date*: 2006-02-22
    Sponsor Name:UF de méthodologie en recherche clinique
    Full Title: Efficacité de la rapamycine dans la prévention secondaire des cancers cutanés chez les transplantés rénaux. Etude ouverte randomisée Rapamycine vs anticalcineurines
    Medical condition: To evaluate the impact of two imnosupressive regimens on the incidence of skin cancers among patients who has a first spinocellular skin cancer after renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003589-25 Sponsor Protocol Number: Levo-AKI Start Date*: 2014-11-11
    Sponsor Name:Sahlgrenska Universitetssjukhuset/Sahlgrenska
    Full Title: The effect of levosimendan, on renal blood flow, function and oxygen uptake during acute renal failure after cardiac surgery
    Medical condition: Acute kidney injury postoperatively in connection with heart surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005867-33 Sponsor Protocol Number: 13701 Start Date*: 2009-03-10
    Sponsor Name:Bayer HealthCare AG
    Full Title: Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Primovist/Eovist in patients with mode...
    Medical condition: Patients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10038469 Renal impairment NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002539-27 Sponsor Protocol Number: IntraRenalTac Start Date*: 2019-09-23
    Sponsor Name:Oslo University Hospital – Rikshospitalet
    Full Title: Association between intrarenal tacrolimus concentration and development of renal interstitial fibrosis in renal transplant recipients
    Medical condition: Development of renal interstitial fibrosis in renal transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000416-91 Sponsor Protocol Number: CA186001 Start Date*: 2007-07-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or Locally Advanced Solid Malignanci...
    Medical condition: Patients with Metastatic or Locally Advanced Solid Malignancies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025650 Malignant melanoma LLT
    9.1 10038395 Renal carcinoma LLT
    9.1 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002455-33 Sponsor Protocol Number: D8480C00030 Start Date*: 2006-11-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell ...
    Medical condition: Renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038410 Renal cell carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005403-17 Sponsor Protocol Number: KH-MS-JAW-01 Start Date*: 2007-12-10
    Sponsor Name:GE Healthcare
    Full Title: A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma
    Medical condition: Upper urinary tract (ureters and pyela/renal pelvises) urothelial cell carcinoma for which blue light uretero-renoscopy and biopsies are performed for diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026431 Malignant neoplasm of renal pelvis and ureter transitional cell regional LLT
    9.1 10038497 Renal pelvis and ureter transitional cell cancer localized LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003298-24 Sponsor Protocol Number: EVITAESTEROIDE-12 Start Date*: 2014-06-26
    Sponsor Name:Sociedad Andaluza de Trasplante de Órganos y Tejidos (SATOT)
    Full Title: Steroid withdrawal and novo donor-specific anti-HLA antibodies in renal transplant patients: a prospective, randomized and controlled study in parallel groups.
    Medical condition: Kidney transplantaion
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002556-41 Sponsor Protocol Number: TRX 1.0 Start Date*: 2008-02-07
    Sponsor Name:Trimed Biotech GmbH
    Full Title: A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination...
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 11  12  13  14  15  16  17  18  19  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 07:02:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA